A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Taxane Regimen

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00479635
• Other study ID #: TPI 287-04
• Status: Terminated
• Phase: Phase 2
• First received: May 24, 2007
• Last updated: January 9, 2014
• Start date: January 2007
• Est. completion date: August 2008

Study information

• Verified date: January 2014
• Source: Cortice Biosciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.

Description:

This is an open-label, multi-center, 2-stage Simon design, Phase 2 study of TPI 287 in patients with metastatic, hormone-refractory prostate cancer. All patients must have received prior taxane therapy. Up to 80 patients will be enrolled and stratified based on duration of cumulative exposure to a single prior taxane regimen. A single taxane regimen is considered to he a taxane or taxane containing therapy administered on a defined schedule with no more than 2 months' interruption between treatments, and total exposure will be assessed by the number of months on that schedule.

One stratum (up to 40 patients) will consist of patients who have had over 3 months (up to a maximum of 10 months) exposure to a taxane regimen, who then have documented progression of disease (initially taxane sensitive). The second stratum (up to 40 patients) will consist of patients considered primarily resistant to taxanes who have had documented progressive disease as best response after exposure to a single taxane regimen for less than or equal to 3 months. Patients may have received prior hormonal therapy and/or bisphosphonates and may continue on these therapies.

In the first stage of the trial, 22 patients in each stratum will be treated with TPI 287 intravenously every 21 days. If 1 or fewer patients in either stratum demonstrate a response in this first stage, the trial will be discontinued for that stratum. Otherwise, an additional 18 patients in the stratum showing 2 or more responses will be enrolled in the second stage of the study. If 4 or fewer patients demonstrate a response in the total study population in either stratum from stages 1 and 2, then the drug will not be considered of interest in prostate cancer for patients as defined in that stratum.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 26
• Est. completion date: August 2008
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological or cytological evidence of adenocarcinoma of the prostate and have metastatic disease.

• Patients must have received only one prior regimen for their advanced disease. This regimen must have included a taxane.

• First Stratum Eligibility: Patients must have advanced, metastatic prostate cancer with documented progression after receiving more than three months of treatment, up to a total of 10 months with 1 prior taxane regimen. Prior best response to treatment, and duration of response, will be recorded.

• Second Stratum Eligibility: Patients must have advanced, metastatic prostate cancer that has progressed as best response despite three months or less of treatment with 1 prior taxane regimen.

• Must have castrate levels of testosterone less than 50 ng/mL

• Must have an ECOG Performance Score of 0 or 1

• Must be age 18 or older

• Must be able to read, understand and sign informed consent

• Serum creatinine less than or equal to 2.0 mg/dL

• Total bilirubin less than or equal to 2.0 mg/dL

• SGOT/SGPT less than or equal to 3 times the ULN

• ANC greater than or equal to 1500/UL

• Platelet count greater than or equal to 100,000/UL Recovered from the effects of prior surgery, radiotherapy or other antineoplastic therapy.

Exclusion Criteria:

• Active infection or with a fever greater than or equal to 38.5 degrees centigrade within 3 days of first scheduled day of dosing

• More than one prior systemic therapy for HRPC beyond androgen-ablative therapy. Prior systemic therapy may have been administered for metastatic disease or as adjuvant therapy

• Has received radiotherapy to greater than 30% of their active bone marrow

• History of prior malignancy within the past 5 years except for curatively treated non-melanoma skin cancer

• Impending fracture of a weight bearing bone

• Known hypersensitivity to any of the components of TPI 287

• Receiving concurrent investigational therapy or who have received investigational therapy within 30 days of study start

• Grade 2 peripheral neuropathy

• NYHA Class 3 or 4 congestive heart failure

• Any medial condition that would interfere with ability to sign ICF, cooperate and participate in the study or interfere with interpretation of results

• History of allogenic transplant

• Know HIV or Hepatitis B or C positive

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• TPI 287
160 mg/m2 every three weeks for six cycles
• TPI 287
160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.

Locations

Country	Name	City	State
United States	Kansas City Cancer Center South	Kansas City	Missouri
United States	University of Kentucky	Lexington	Kentucky
United States	St. Barnabas Medical Center	Livingston	New Jersey
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Tennessee Oncology, PLLC	Nashville	Tennessee
United States	Comprehensive Cancer Center at Desert Mountain	Palm Springs	California

Sponsors (1)

Lead Sponsor	Collaborator
Cortice Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response		15 months	No
Secondary	Time to progression		15 months	No
Secondary	Duration of response		6 months	No
Secondary	Safety		Continuous	Yes